GDTC stock forecast, quote, news & analysis
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers... Show more
CytoMed Therapeutics (GDTC) Stock Analysis: Off-the-Shelf Cell Therapy Pipeline Hinges on Phase I Progress
Key Takeaways
- CytoMed Therapeutics (GDTC) is a Singapore-based clinical-stage biopharmaceutical company developing "off-the-shelf," donor-derived cell therapies for blood and solid cancers.
- Shares have declined roughly 7% over the trailing 30 days, trading near $0.86, well below the 52-week high of $2.29 and not far from the 52-week low near $0.68.
- The lead candidate, CTM-N2D, is advancing through a first-in-human Phase I trial (ANGELICA) at National University Hospital Singapore, with trial completion targeted for 2026.
- With a market capitalization around $10 million, GDTC is a micro-cap with heavy insider ownership (roughly 70%) and minimal institutional participation, leaving the stock sensitive to clinical news and funding developments.
- The company reported a wider fiscal 2025 net loss and lower cash reserves, underscoring the execution and financing risks common to early-stage biotechs.
- Explore additional details on GDTC's Price Targets, Earnings, and Forecast to support your own research.
- For AI-driven trade ideas across thousands of tickers, explore Trending AI Robots.
Current Market Snapshot
CytoMed Therapeutics trades near $0.86, reflecting a decline of about 7% over the trailing 30 days after closing near $0.93 roughly a month earlier. The stock remains firmly in micro-cap territory with a market capitalization of approximately $10 million, and average daily volume is modest, which can amplify price swings on relatively small order flow.
The shares sit well below their 52-week high of $2.29 and close to the low end of a range that has tested levels near $0.68. With insiders holding roughly 70% of shares outstanding and institutional ownership near 0.3%, the trading float is thin, and sentiment can shift quickly around clinical milestones, financing announcements, and broader risk appetite in the biotechnology sector.
CytoMed Therapeutics (GDTC) Business Overview and Competitive Position
Incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR), CytoMed develops allogeneic, donor-derived cell-based immunotherapies designed to be more affordable and scalable than conventional autologous CAR-T treatments, which require engineering a patient's own cells.
The lead program, CTM-N2D, uses gamma delta T cells modified to express a chimeric antigen receptor targeting NKG2D ligands found on many cancers. It can be infused without donor-patient matching and is being evaluated in the ANGELICA Phase I trial across advanced solid and hematological malignancies. The broader pipeline includes CTM-GDT (unmodified gamma delta T cells), iPSC-derived gamma delta NKT cell candidates, and CTM-MSC for cartilage injury. The company also operates through its LongevityBank subsidiary in cord blood-derived natural killer cell development.
Recent Developments Driving GDTC
CytoMed's investment narrative is anchored to clinical execution. The ANGELICA trial has completed dose level 1 and advanced to dose level 2, with six patients treated across two dose levels and escalation toward the final dose underway; management has targeted trial completion in 2026. In parallel, a December 2025 memorandum of understanding with Universiti Malaya set the stage for a Phase I trial of unmodified gamma delta T cells (CTM-GDT) in Malaysia, with an investigational new drug submission targeted before mid-2026.
Financial results reported for fiscal 2025 showed revenue and other operating income of about $0.78 million and a wider net loss of roughly $3.1 million, while cash declined to about $1.63 million from $3.87 million. These figures highlight the funding and dilution considerations that weigh on micro-cap biotechs. The company has also cited preclinical work co-authored with MD Anderson Cancer Center supporting CTM-GDT's potential in acute myeloid leukemia. The most recently available analyst rating on the stock was a Sell with a $0.81 price target.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI-driven trading bots that monitor thousands of tickers, and its Trending AI Robots page surfaces only the top-performing and most relevant strategies at any given time. These bots differ in approach, holding timeframe, and performance metrics, giving traders a filtered view of the signals that are currently standing out across the market. The curated list is refreshed based on recent results, making it a practical starting point for investors looking to complement their own analysis with quantitative, rules-based trade ideas.
2026 Outlook and What Investors Should Watch
Looking ahead, the key catalysts for CytoMed revolve around clinical data and regional expansion. Investors will be monitoring safety and tolerability readouts from the ANGELICA Phase I trial and any progress toward a Phase II plan, as well as the submission and initiation of the Malaysia CTM-GDT trial. Updates on the MD Anderson AML collaboration and the LongevityBank cord blood program could also shape the long-term pipeline narrative.
On the financial side, cash runway, any new financing, and the pace of research spending will remain central to sentiment given the company's thin balance sheet and limited institutional base. As with most early-stage oncology developers, the outlook is tied to execution on trial milestones and the ability to fund continued development without excessive shareholder dilution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for GDTC turns negative, indicating new downward trend
GDTC saw its Momentum Indicator move below the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In 71 of the 77 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for GDTC turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 37 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GDTC moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GDTC crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where GDTC advanced for three days, in 115 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GDTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. GDTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.139) is normal, around the industry mean (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (36.765) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology